Xlrab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed to manage gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. The synergistic action of these two agents in Xlrab-DSR Capsule offers comprehensive management of acid-related dyspepsia and motility disorders, improving patient comfort and quality of life. This combination is typically prescribed for short-term use under medical supervision, with dosage adjusted according to clinical response. Patients should be advised to adhere strictly to prescribed doses and report any adverse effects such as headache, dry mouth, or gastrointestinal disturbances. Xlrab-DSR Capsule is contraindicated in patients with hypersensitivity to either component and should be used cautiously in those with underlying cardiac or hepatic conditions.